Dr Arvind Dasari speaks to ecancer about the clinical utility of including circulating tumour DNA (ctDNA) monitoring in standard of care colorectal cancer surveillance.

Dr Dasari explores new findings showing how circulating tumour DNA (ctDNA) testing can transform colorectal cancer follow-up after surgery. He says that detecting oligometastatic disease (OMD) is key to offering curative metastasis-directed therapy (MDT).

The results form this trial show that ctDNA testing detects recurrence and treatable metastases far better than standard methods. ctDNA-positive patients are much more likely to receive potentially curative MDT. 

Dr Dasari highlights that future CRC follow-up should consider personalised surveillance based on ctDNA results.